Schwab Charles Investment Management Inc. increased its position in shares of Mednax, Inc (NYSE:MD) by 5.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 295,514 shares of the company’s stock after acquiring an additional 15,715 shares during the period. Schwab Charles Investment Management Inc. owned about 0.32% of Mednax worth $17,841,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MD. BlackRock Inc. boosted its position in shares of Mednax by 5,766.0% during the 1st quarter. BlackRock Inc. now owns 8,229,340 shares of the company’s stock worth $570,952,000 after acquiring an additional 8,089,052 shares in the last quarter. Clearbridge Investments LLC boosted its position in shares of Mednax by 33.1% during the 1st quarter. Clearbridge Investments LLC now owns 2,048,277 shares of the company’s stock worth $142,109,000 after acquiring an additional 508,863 shares in the last quarter. Longview Partners Guernsey LTD boosted its position in shares of Mednax by 10.3% during the 2nd quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock worth $303,267,000 after acquiring an additional 467,845 shares in the last quarter. Fiduciary Management Inc. WI boosted its position in shares of Mednax by 2,873.3% during the 1st quarter. Fiduciary Management Inc. WI now owns 442,725 shares of the company’s stock worth $30,716,000 after acquiring an additional 427,835 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Mednax by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 7,512,485 shares of the company’s stock worth $521,216,000 after acquiring an additional 339,932 shares in the last quarter.

A number of analysts have weighed in on the stock. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Robert W. Baird restated a “hold” rating and issued a $47.00 target price on shares of Mednax in a research report on Sunday, September 3rd. Stephens upgraded shares of Mednax from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $55.00 to $68.00 in a research report on Thursday, June 22nd. Jefferies Group LLC restated a “hold” rating and issued a $53.00 target price (up previously from $50.00) on shares of Mednax in a research report on Thursday, July 6th. Finally, ValuEngine lowered shares of Mednax from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company. Mednax has an average rating of “Hold” and a consensus target price of $58.89.

ILLEGAL ACTIVITY WARNING: “Schwab Charles Investment Management Inc. Has $17.84 Million Position in Mednax, Inc (MD)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/23/schwab-charles-investment-management-inc-has-17-84-million-position-in-mednax-inc-md.html.

Mednax, Inc (MD) opened at 42.14 on Friday. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 13.42 and a beta of 0.40. Mednax, Inc has a one year low of $40.78 and a one year high of $72.13. The stock’s 50 day moving average is $43.21 and its 200-day moving average is $56.37.

Mednax (NYSE:MD) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company had revenue of $843.00 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the prior year, the company earned $1.03 EPS. The firm’s revenue was up 9.2% on a year-over-year basis. On average, equities research analysts expect that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.

In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.